(PFE) Pfizer Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PFE) Pfizer Inc. Bundle
Download Your Competitive Advantage
This Pfizer Inc. BCG Matrix is a ready-made strategic analysis that helps you see how the company’s products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework. The page already shows a real preview of the actual report content, so you can review what you’re getting before buying. Purchase the full version to access the complete ready-to-use analysis.
Stars
Vyndaqel family 5B+ ATTR growth
Pfizer’s Vyndaqel/Vyndamax franchise posted about $5.0 billion in 2024 revenue, making it one of the company’s biggest growth engines. ATTR cardiomyopathy diagnosis and treatment rates kept rising into 2025 as awareness and screening expanded. With a leading share in a still-growing rare-disease market, the franchise fits the Star quadrant.
Padcev 1B+ urothelial cancer growth
Padcev gained scale after the EV-302 combo with pembrolizumab became a first-line standard for locally advanced or metastatic urothelial cancer, with median overall survival of 31.5 vs 16.1 months and median PFS of 12.5 vs 6.3 months. Astellas reported FY2024 Padcev sales of ¥189.4 billion, showing 1B-plus market scale. That makes it a Star candidate for Pfizer: fast growth, stronger penetration, and a wider bladder-cancer market through 2025.
Prevnar 20 6B pneumococcal franchise
Prevnar 20 anchors Pfizer Inc.’s pneumococcal franchise, which is about $6B in scale. In 2025, adult and pediatric PCV20 use kept the business large, and the 20-valent design gave broad serotype coverage. High share in a broad vaccine market supports Star status.
Nurtec ODT 1B migraine brand
Nurtec ODT is a $1B-plus migraine brand for Pfizer Inc., and it is used for both acute treatment and prevention. The CGRP class keeps taking share from older migraine drugs, so Pfizer has a strong position in a still-expanding market. That mix of scale, dual use, and category growth fits a Star in the BCG Matrix.
- 1B-plus brand
- Acute and preventive use
- CGRP share gain
- Star profile
Abrysvo RSV launch brand
Abrysvo has two approved RSV paths: adults 60+ and maternal vaccination, which gives Pfizer Inc. a broader launch base than a single-use brand. RSV vaccination is still in an adoption phase, so the category is early and growth can stay steep if uptake keeps building. The maternal niche is especially important because it opens a second, high-value demand pool and supports a Star label in the BCG matrix.
- Two indications widen launch reach
- Early market means room to grow
- Maternal use is the key growth engine
Pfizer’s 2025 Star Brands: Scale, Growth, and Expanding Use
Pfizer Inc.’s Stars are the franchises with strong 2025 scale and clear growth: Vyndaqel/Vyndamax near $5.0B in 2024 sales, Prevnar 20 around $6B, and Nurtec ODT above $1B. Padcev and Abrysvo also fit, backed by 2025 market expansion and broader use in bladder cancer and RSV.
| Brand | 2025 Star signal |
|---|---|
| Vyndaqel/Vyndamax | $5.0B 2024 sales |
| Prevnar 20 | ~$6B scale |
| Nurtec ODT | >$1B and growing |
| Padcev | 1L bladder cancer growth |
| Abrysvo | 2 RSV indications |
What is included in the product
Detailed Word Document
Pfizer’s BCG Matrix maps its drug portfolio to spot growth bets, cash cows, and potential divestments.
Editable Excel File
One-page Pfizer BCG Matrix to quickly spot stars, cash cows, and drag points.
Reference Sources
Lists credible sources behind Pfizer Inc. claims to boost trust, speed due diligence, and support sharper decisions.
Cash Cows
Comirnaty 5B+ mature COVID vaccine
Comirnaty stayed a key cash cow for Pfizer Inc., with 2024 sales of about $5.3 billion, even as COVID demand cooled from pandemic peaks. The market is now booster-led and seasonal, not hypergrowth-driven, so cash flow is steadier but slower.
That makes Comirnaty fit the BCG Cash Cow box: high share in a mature market, low growth, and strong monetization of Pfizer’s global vaccine reach.
Premarin family long-running women health
Premarin has been in women’s health for decades, and its demand is steady because postmenopausal hormone therapy is a mature, low-growth category. High brand recognition and a long safety/usage history support repeat prescriptions, which is why it fits the Cash Cow bucket in Pfizer Inc.'s BCG Matrix.
BeneFIX hemophilia B legacy brand
BeneFIX (nonacog alfa) is Pfizer Inc.'s long-running recombinant factor IX brand, used in a mature hemophilia B market that remains steady because treatment is lifelong. Hemophilia B makes up about 15% of hemophilia cases, or roughly 1 in 25,000 male births, so demand is small but durable. That profile supports steady cash flow with limited growth pressure.
Retacrit mature ESA biosimilar
Retacrit is Pfizer Inc.'s mature epoetin alfa-epbx biosimilar in anemia and nephrology, where pricing is tight but hospital and dialysis demand stays steady. That makes it a classic Cash Cow: low growth, durable volume, and recurring use in chronic kidney disease care.
Pfizer still benefits from established formulary access and repeat treatment cycles, even as biosimilar competition keeps margins under pressure. The asset fits a harvest-and-defend role inside Pfizer Inc.'s BCG Matrix.
- Stable dialysis-channel volume
- Price pressure, but sticky demand
- Mature biosimilar cash flow
Eliquis recurring anticoagulant revenue
In late 2025, Eliquis still looks like a Cash Cow for Pfizer Inc. because it sits in a mature anticoagulant market with steady repeat prescribing, not a high-growth launch curve. Pfizer reported about $7.2 billion of Eliquis revenue in 2024, and that kind of scale points to durable, recurring cash flow rather than heavy reinvestment needs.
- About $7.2B Pfizer revenue in 2024
- Large, established anticoagulant market
- Repeat prescriptions support stable demand
- Fits Cash Cow, not rapid-growth launch
Pfizer’s cash cows keep delivering billions
Pfizer Inc.'s cash cows remain mature, high-share brands with steady repeat use and limited growth. Eliquis brought about $7.2B in 2024 sales, while Comirnaty still added about $5.3B, showing durable cash flow even as demand normalized.
| Brand | 2024 sales | BCG role |
|---|---|---|
| Eliquis | $7.2B | Cash Cow |
| Comirnaty | $5.3B | Cash Cow |
What You See Is What You Get
Pfizer Inc. Reference Sources
The Pfizer Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No placeholders, no demo pages—just the full, ready-to-use report.
Once purchased, this final version is instantly available for download and review. It’s formatted for clear strategic analysis and professional use.
What you preview is what you get, with no changes or surprises. Use it for planning, presentations, or competitive analysis with confidence.
Dogs
Ibrance 3B and declining
Ibrance remains a Dog in Pfizer Inc.’s BCG Matrix. FY2024 sales fell to about $2.7B from $3.1B in FY2023 as Verzenio and Kisqali kept taking share in the CDK4/6 breast-cancer class. The market is still large, but Ibrance’s shrinking revenue and weaker growth momentum show eroding position, not a star or cash cow.
Xeljanz pressure from JAK rivals
Xeljanz sits in a crowded JAK market, and the class still carries FDA boxed-warning safety scrutiny tied to higher risks seen in the 2021 ORAL Surveillance data. Pfizer’s Xeljanz sales were about $1.0 billion in 2024, down from its peak, showing weak growth and heavy rivalry from newer immunology drugs. That profile fits a Dog in the BCG matrix.
Paxlovid post-peak antiviral
Paxlovid fits Pfizer Inc.’s Dogs bucket by end-2025: it peaked at about $18.9 billion in 2022, then COVID treatment demand fell hard as the emergency phase ended. Pfizer Inc. said Paxlovid sales stayed far below peak levels in 2024, showing a low-growth, low-share asset.
Xtandi mature prostate cancer therapy
Xtandi is a mature prostate cancer asset for Pfizer Inc., with limited room to expand as newer androgen-receptor options keep pressure on pricing and share. In 2025, the prostate cancer drug market stayed crowded, and Xtandi’s growth looked modest versus faster-growing oncology launches. That makes the asset fit a Dog profile in Pfizer Inc.’s BCG Matrix.
- Mature brand, low growth
- Intense prostate cancer rivalry
- Weak upside for Pfizer Inc.
Inflectra commoditized biosimilar
Inflectra is a commoditized infliximab biosimilar in a crowded market with multiple rivals, so price cuts, not differentiation, drive demand. Pfizer's own biosimilar portfolio has faced thin margins here, and Inflectra’s growth is capped as more payers and hospitals switch to the lowest-cost option. That makes it a clear Dog in the BCG Matrix.
- High pricing pressure
- Limited growth runway
- Low-margin biosimilar
- Dog classification
Pfizer’s Dog Drugs Keep Losing Ground
Pfizer Inc.’s Dog assets stay under pressure: Ibrance fell to about $2.7B in FY2024, Xeljanz to about $1.0B, Paxlovid was far below its $18.9B 2022 peak, and Inflectra faces low-price biosimilar rivalry. These drugs show weak growth, shrinking share, and limited upside.
| Drug | FY2024 sales | Dog signal |
|---|---|---|
| Ibrance | $2.7B | Declining |
| Xeljanz | $1.0B | Stalled |
Question Marks
Hympavzi early hemophilia entrant
Hympavzi is Pfizer Inc.’s early hemophilia prophylaxis entrant, so it sits in the Question Marks bucket: low share today, but with room to grow. Non-factor prevention is the faster-expanding part of hemophilia care, and Pfizer’s 2024 launch gives it a real shot to win share. It needs spending on access, data, and sales now to turn momentum into a Star.
Elrexfio early multiple myeloma launch
Elrexfio is still in the launch phase, so its sales base is small versus Pfizer Inc.’s larger oncology portfolio. Multiple myeloma is a growing market, but it is crowded with strong rivals like Johnson & Johnson and Bristol Myers Squibb, so share gains are slow. That puts Elrexfio in Question Marks: clear upside, but low current share and still limited traction.
Litfulo small alopecia areata share
Litfulo is still a small brand in alopecia areata, a disease that affects about 2% of people worldwide. Pfizer launched Litfulo in 2023, so the franchise is still early in its buildout. It is growing in a dermatology market led by bigger, more established rivals, which fits a classic Question Mark in the BCG Matrix.
Zavzpret crowded migraine market
Zavzpret sits in a growing but crowded acute-migraine market, where CGRP drugs compete with triptans and newer rivals. Pfizer launched Zavzpret in 2023, so the brand is still early and sales scale is modest versus category leaders. Low share in an expanding market makes it a clear Question Mark in Pfizer Inc.'s BCG Matrix.
- Growing migraine category
- Heavy competition
- Still small brand
- Question Mark status
Velsipity ulcerative colitis launch
Velsipity is a newer ulcerative colitis therapy, launched after U.S. FDA approval in 2023 for adults with moderately to severely active disease. In a large, growing IBD market, Pfizer Inc. still has a small share here, so the brand fits Question Mark status.
It needs faster uptake in gastroenterology, stronger formulary access, and more repeat prescribing before it can become a Star.
- New launch, still early share
- IBD demand remains large and growing
- More uptake is needed to scale
Pfizer’s New Launches: Early Traction, Big Potential
Pfizer Inc.’s Question Marks are newer, low-share launches in growing markets: Hympavzi, Elrexfio, Litfulo, Zavzpret, and Velsipity. They all need more spend, access wins, and repeat use to move up from early traction; until then, their upside is real but unproven.
| Brand | 2025/2026 view | Why |
|---|---|---|
| Hympavzi | Question Mark | 2024 launch, early hemophilia share |
| Elrexfio | Question Mark | Small base in crowded myeloma |
| Litfulo | Question Mark | 2023 launch, early alopecia build |
| Zavzpret | Question Mark | 2023 launch, modest migraine share |
| Velsipity | Question Mark | 2023 FDA launch, still early IBD uptake |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.